Company: REVB
Filing Date: 2025-04-04
Form Type: DRS
Source: 0001213900-25-029022
Chunk: 92

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-04-04
Form: DRS
Chunk 92
---
 a Certificate of Amendment to our Third Amended and Restated Certificate of Incorporation to change the authorized common stock from 100,000,000 to 500,000,000shares and effect a reverse stock split of our outstanding shares of common stock at a specific ratio within a range of one -for -twenty(1 -for-20) to a maximum of a one -for -onehundred (1 -for-100) split. On January 30, 2023, we filed the Certificate of Amendment which set the authorized common stock to 500,000,000 and effected a 1 -for-35reverse stock split of our outstanding shares of common stock as of 12:01 a.m. Eastern Standard Time on February 1, 2023. Business Strategy and Pipeline Revelation is developing a pipeline of potential high -valueproducts based on Gemini.Gemini is Revelation’s proprietary formulation of phosphorylated hexaacyl disaccharide (“PHAD ®”) an established Toll -likereceptor 4 (TLR4”) agonist that can stimulate the human body’s innate immune response to prevent and treat disease. 56 Our current Gemini based programs consist of: Gemini -AKI, which is being developed for the prevention of AKI; Gemini -CKDfor the treatment of CKD; and Gemini -PSI, which is being developed for the prevention of PSI. Revelation’s pipeline is summarized in the figure below: The Gemini Platform Our current therapeutic candidates are all based on our proprietary Gemini formulation of PHAD ®, a synthetic version of monophosphoryl lipid A (“MPLA”), that is known to stimulate TLR4. Stimulation of TLR4 via Gemini leads to a more controlled production of varied cytokines and chemokines which modulate the activity of the innate and adaptive immune response, relative to a lipopolysaccharide, a traditional TLR4 agonist. This “Immunostimulatory Preconditioning” with Gemini prepares the body to better guard against a rapid upregulation of multiple pro -inflammatoryand microbial gene products and proteins, such as pathogen -associatedmolecular patterns (“PAMPS”) and damage -associatedmolecular patterns (“DAMPS”) (damage -associatedmolecular proteins) (Zwirner 2017, Hernandez 2019, Ismaeli 2002). Modulated activities may include stimulation and recruitment of infection fighting immune cells, reduction of inflammation, and/or regulation of inflammation depending on